SYShinya Yamamoto

Shinya Yamamoto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shinya Yamamoto has a total of 113 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Timing dependent associations of acute phase laboratory and antibody parameters with post-acute sequelae of SARS-CoV-2 infection in unvaccinated individuals

    by Shinya Yamamoto, Takeshi Ohtsuka, Yoshiro Kishi, Koh Okamoto, Takeya Tsutsumi, Chungen Qian, Fan He, Kyoji Moriya, Tatsuhiko Kodama, Makoto Kurano

    Introduction: Post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) affects a substantial minority of individuals after acute COVID-19, and immune dysregulation is widely implicated in its pathogenesis. Reported associations between SARS-CoV-2-specific antibody responses and PASC have nonetheless been inconsistent. Because antibody levels change rapidly in the weeks after symptom onset, the timing of sampling may itself account for much of this heterogeneity, yet few studies have examined humoral responses along the time axis from symptom onset in combination with routinely available hematological, biochemical, and coagulation parameters. Methods: Eight hundred seventy-two serial serum samples were retrospectively analyzed from 213 unvaccinated individuals experiencing their first SARS-CoV-2 infection, sampled between April 2020 and June 2021, before vaccine rollout and before the emergence of Omicron; 13 individuals subsequently met the World Health Organization definition of PASC. Sixty-seven parameters, comprising antiviral antibodies, autoantibodies and immune markers, complete blood count, biochemistry and coagulation tests, were compared between groups within four windows defined by days since symptom onset: ≤ 7, 8–14, 15–28, and > 28 days. Results: The pattern of association shifted markedly across windows. Within seven days of onset, innate inflammatory and coagulation markers predominated. Between days 8 and 14, when adaptive humoral responses first become measurable, red cell indices differed between groups, with lower mean corpuscular hemoglobin concentration remaining significant when each patient contributed a single value. Anti-spike IgM levels tended to be higher in individuals who later developed PASC, although the difference was not statistically significant. Exploratory multivariable models combining humoral and hematological features discriminated better than either domain alone, although the small number of PASC cases precludes any claim of predictive validity. Discussion: These findings identify days 8–14 after symptom onset as a potentially informative window during which acute-phase laboratory parameters, and possibly early humoral responses, differ between individuals who do and do not subsequently develop PASC, and suggest that the timing and quality of the early antibody response, rather than antibody magnitude measured at a single late time point, merit systematic investigation in PASC.

  • Open Access

    Hepatitis A vaccination during ventricular assist device support in heart transplant candidates: immunogenicity and safety in a single-center cohort

    by Masahiro Arima, Shinya Yamamoto, Maho Adachi-Katayama, Koh Okamoto, Masahiko Ando, Shu Okugawa, Minoru Ono, Takeya Tsutsumi

    Vaccination is among the cornerstones of infectious disease prevention in heart transplant candidates and recipients. Guidelines recommend an inactivated hepatitis A virus vaccine for heart transplant candidates, many of whom are on ventricular assist devices and at risk of hepatitis A virus exposure. However, data on the immunogenicity and safety of hepatitis A virus vaccines in these patients are lacking.This retrospective, observational, single-center study was conducted at our outpatient clinic between December 2019 and December 2025. The study participants were heart transplant candidates with ventricular assist devices aged ≥16 years who tested negative for anti-hepatitis A virus immunoglobulin G at baseline and completed the inactivated hepatitis A virus vaccination series. Anti-hepatitis A virus immunoglobulin G titers were measured after vaccination using a chemiluminescent immunoassay. Thirty-five individuals were included in the study. Immunosuppressive agents were used in four patients (11.4%). All participants achieved seroconversion at a median of 1 month after vaccination. The reverse cumulative distribution of the Anti-hepatitis A virus immunoglobulin G sample/cutoff values indicated that an adequate antibody response was achieved in individuals with ventricular assist devices. Adverse events of the vaccine were minor; two patients (6%) experienced local pain, and two (6%) subcutaneous hemorrhage. Seroconversion in patients with ventricular assist devices was high. hepatitis A virus vaccination should be completed before transplantation in heart transplant candidates, if indicated.

  • Open Access

    Sphingolipid and glycerophospholipid profiling in post-acute sequelae of SARS-CoV-2 infection

    by Shinya Yamamoto, Makoto Kurano, Koh Okamoto, Masayuki Kubota, Takeya Tsutsumi, Junken Aoki, Kyoji Moriya

    Post-acute sequelae of severe acute respiratory syndrome coronavirus 2 infection (PASC) is a heterogeneous multisystemic condition with unclear pathogenesis. Emerging evidence suggests that the disruption in metabolism, including lipid metabolism, can be involved in the pathogenesis of coronavirus disease 2019 (COVID-19). We previously measured the bioactive lipids in acute COVID-19, and we hypothesized that bioactive lipid dysregulation play a role in PASC pathogenesis. We conducted targeted LC-MS/MS analysis of sphingolipids and glycerophospholipids in serum samples from individuals with acute-phase COVID-19, including those who developed PASC, alongside healthy controls. We systematically examined lipidomic changes in serum samples, including analyses using linear mixed model, and found that no sphingolipid or glycerophospholipid species differed between the COVID-19 and PASC groups. Although these results are exploratory, the group x time interaction in the linear mixed model suggested that phosphatidylglycerol (PG) may represent a bioactive lipid distinguishing the COVID-19 and PASC groups. Given the small PASC sample size and that the signal was detected only at specific time points, these findings are hypothesis generating and should be confirmed in larger, adequately powered, and independently validated cohorts.


  • Open Access

    From Diagnostic Challenge to Clinical Success: Rapid Multiplex PCR Identification of Cryptosporidium in HIV ‐Associated Refractory Diarrhea: A Case Report

    by Yudai Kono, Mayu Arase, Kohei Ukai, Keiko Soneda, Shinya Yamamoto, Kazuhiko Ikeuchi, Eisuke Adachi, Yusuke Nomura, Yoshimi Higurashi, Shinji Izumiyama, et al.

    Cryptosporidiosis remains a challenge in people with HIV despite its decreased incidence in developed countries. We report a case of severe diarrhea in a person with HIV where Gram stain findings prioritized cryptosporidium in the differential diagnosis. Multiplex PCR enabled early diagnosis and treatment, highlighting its value in clinical management.

  • Open Access

    Clinical impact of the use of chronic suppressive antibiotics against recurrent ventricular assist device infections

    by Shinya Yamamoto, Koh Okamoto, Hiraku Kumamaru, Makoto Saito, Hiroshi Ito, Marie Yamashita, Yoshiaki Kanno, Mahoko Ikeda, Sohei Harada, Shu Okugwa, et al.

    Ventricular assist device (VAD) infections are frequent causes of hospital readmission. The risk factors and optimal preventive strategies for such, including chronic suppressive antibiotics (CSA), remain uncertain. We performed a single-center, retrospective, observational cohort study assessing continuous flow VAD recipients who underwent implantation between 2008 and 2018 in Japan. From primary VAD infection (VADI), we followed the patients for recurrent infection, defined as relapsing VAD-specific (e.g., localized infections) or VAD-related (e.g., bacteremia) infections requiring hospital readmission. CSA was defined as the use of oral antimicrobial agents continued beyond initial antibiotic use until transplantation, VAD withdrawal, VADI recurrence, or death. Survival analysis was performed to identify risk factors for recurrent infection accounting for competing risks (e.g., deaths and transplants). Among 163 eligible patients, 76 patients had VADIs. The main causative organism in primary VADI was Staphylococcus aureus (63%, 48/76). Among them, 41 had recurrent infections, whereas 35 had none during the follow-up period (median, 335 days). Thirty-six patients received CSA for a median of 478 days. Although CSA was associated with a decreased risk of recurrent infection [adjusted sub-distribution hazard ratio (SHR), 0.40; 95% confidence interval (CI), 0.18–0.89; P = 0.03], this protective effect was observed only after primary VAD-specific infection (SHR, 0.28; 95% CI, 0.12–0.64; P < 0.01) but not after VAD-related infection. Surgical procedures during primary VADI were associated with an increased risk (SHR, 2.00; 95% CI, 1.10–3.66; P = 0.02). One patient had an adverse drug reaction. CSA may be an effective approach to limit relapsing VADIs following a primary VAD-specific infection with minimal adverse events. IMPORTANCE: Ventricular assist device infections (VADIs) are a significant complication leading to hospital readmissions. However, the risk factors and optimal preventive strategies for VADI remain unclear. This study investigated the effectiveness of chronic suppressive antibiotic therapy in patients with VADI. We found that the use of chronic suppressive antibiotic therapy was associated with a reduction in the risk of VADI recurrence with few adverse reactions. Our findings suggest the potential benefit of chronic suppressive antibiotics in preventing infections in selected cases. Our findings are relevant for the management of patients with ventricular assist devices awaiting heart transplantation, providing valuable insights for clinical practice.


  • Open Access

    Airway surveillance and lung viral control by memory T cells induced by COVID-19 mRNA vaccine

    by Brock Kingstad-Bakke, Thomas Cleven, Hailey Bussan, Boyd L. Yount, Ryuta Uraki, Kiyoko Iwatsuki-Horimoto, Michiko Koga, Shinya Yamamoto, Hiroshi Yotsuyanagi, Hongtae Park, et al.

    Although SARS-CoV-2 evolution seeds a continuous stream of antibody-evasive viral variants, COVID-19 mRNA vaccines provide robust protection against severe disease and hospitalization. Here, we asked whether mRNA vaccine–induced memory T cells limit lung SARS-CoV-2 replication and severe disease. We show that mice and humans receiving booster BioNTech mRNA vaccine developed potent CD8 T cell responses and showed similar kinetics of expansion and contraction of granzyme B/perforin-expressing effector CD8 T cells. Both monovalent and bivalent mRNA vaccines elicited strong expansion of a heterogeneous pool of terminal effectors and memory precursor effector CD8 T cells in spleen, inguinal and mediastinal lymph nodes, pulmonary vasculature, and most surprisingly in the airways, suggestive of systemic and regional surveillance. Furthermore, we document that: (a) CD8 T cell memory persists in multiple tissues for > 200 days; (b) following challenge with pathogenic SARS-CoV-2, circulating memory CD8 T cells rapidly extravasate to the lungs and promote expeditious viral clearance, by mechanisms that require CD4 T cell help; and (c) adoptively transferred splenic memory CD8 T cells traffic to the airways and promote lung SARS-CoV-2 clearance. These findings provide insights into the critical role of memory T cells in preventing severe lung disease following breakthrough infections with antibody-evasive SARS-CoV-2 variants.


  • Open Access

    The human microbiome and COVID-19: A systematic review

    by Shinya Yamamoto, Makoto Saito, Azumi Tamura, Diki Prawisuda, Taketoshi Mizutani, Hiroshi Yotsuyanagi

    Background: Human microbiotas are communities of microorganisms living in symbiosis with humans. They play an important role in the host immune response to respiratory viral infection. However, evidence on the human microbiome and coronavirus disease (COVID-19) relationship is insufficient. The aim of this systematic literature review was to evaluate existing evidence on the association between the microbiome and COVID-19 in humans and summarize these data in the pandemic era. Methods: We conducted a systematic literature review on the association between the microbiome and COVID-19 in humans by searching PubMed, Embase, and the Cochrane Library, CINAHL, and Web of Science databases for articles in English published up to October 31, 2020. The results were analyzed qualitatively. This study is registered with PROSPERO (CRD42020195982). Results: Of the 543 articles identified by searching databases, 16 in line with the research objectives were eligible for qualitative review: eight sampled the microbiome using stool, four using nasopharyngeal or throat swab, three using bronchoalveolar lavage fluid, and one using lung tissue. Fecal microbiome dysbiosis and increased opportunistic pathogens were reported in COVID-19 patients. Several studies suggested the dysbiosis in the lung microbiome of COVID-19 patients with an abundance of opportunistic pathogens using lower respiratory tract samples. The association between COVID-19 severity and the human microbiome remains uncertain. Conclusion: The human fecal and respiratory tract microbiome changed in COVID-19 patients with opportunistic pathogen abundance. Further research to elucidate the effect of alternation of the human microbiome in disease pathogenesis is warranted.


  • Microbiological analysis of infectious lymphocele: Case series and literature review

    by Shinya Yamamoto, Mahoko Ikeda, Yoshiaki Kanno, Koh Okamoto, Shu Okugawa, Kyoji Moriya


  • Open Access

    Seroconversion against SARS‐CoV‐2 occurred after the recovery in patients with COVID‐19

    by Shinya Yamamoto, Makoto Saito, Etsuko Nagai, Keiko Toriuchi, Hiroyuki Nagai, Hiroshi Yotsuyanagi, Yu Nakagama, Yasutoshi Kido, Eisuke Adachi